Study: No significant long-term benefits found in cocoa extract for AMD

(Image credit: AdobeStock/PixieMe)

An ancillary segment of the COSMOS randomized clinical trial (NCT03205202) found that cocoa extract supplementation over an extended period did not affect the overall occurrence of age-related macular degeneration (AMD) in older patients,¹ according to first author William G. Christen, ScD, for the COSMOS Research Group. He is from the Division of Preventive Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston.

This large study sought to determine if daily supplementation with cocoa extract, a source of flavanols, reduces the occurrence or progression of AMD.

“Although the pathophysiology remains unclear, the consistent observation of decreased choroidal circulation in eyes with AMD^2-4 supports a vascular basis for the disease and has led some investigators to hypothesize that AMD and cardiovascular disease (CVD) may share common underlying mechanisms and risk factors.^5-8 Consistent with this possibility, epidemiologic studies have shown that the risk of AMD is higher in those with CVD compared to those without^9-12 and in those with CVD risk factors, such as elevated blood pressure,^10,12-14 dyslipidemia,^8,12,15-18 higher body mass index,^19,20 and smoking,^21,22 the research team explained.

In addition, nutrition has been thought to contribute to AMD^23,24 and CVD.^25,26 “An area of growing interest is the potential cardiovascular benefits of moderate consumption of cocoa products, with a focus on cocoa flavanols, a group of flavonoids present in the cocoa bean,²⁷” they explained.

Study methods

A total of 21,442 US adults (12,666 women, mean age, 72.1 years) aged 60 years and older were included. They received a cocoa extract supplement and a multivitamin supplement (500 mg/day cocoa flavanols, including 80 mg (−)-epicatechin, a bioactive component in dark chocolate) or placebo to determine if CVD and cancer were prevented. This intervention phase was performed from June 2015 through December 2020.

The primary end point was a composite of incident cases of AMD plus cases of progression to advanced AMD (geographic atrophy, neovascular membrane, retinal pigment epithelium detachment, or disciform scar) among participants with AMD at baseline, the investigators explained.

Ancillary study results

During a median treatment period of 3.6 years, the authors reported that 344 participants (1.6%) had a confirmed AMD event, ie, 316 had incident AMD, 28 progressed to advanced AMD); of these, 159 cases (1.5%) were in the cocoa extract group and 185 cases (1.7%) were in the placebo group ((hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.71-1.08; P =0 .21).

Separate Cox models fitted because of evidence of nonproportional hazards (P = 0.048) indicated a 23% decreased risk in the cocoa extract group during the first 2 years of treatment (HR, 0.77; 95% CI, 0.59-1.01), with no added benefit for treatment beyond 2 years (HR, 1.06; 95% CI, 0.76-1.50). Similar time-dependent findings were observed for visually significant AMD and advanced AMD, the study found.

While cocoa extract supplementation for a median period of 3.6 years did not significantly affect incident AMD and AMD progression, the study could not rule out a possible benefit of supplementation during the first 2 years of treatment. The researchers suggested that further research is warranted to clarify whether long-term cocoa extract supplementation may reduce AMD events.

References

1. Christen WG, Rist PM, Moorthy MV, et al.Cocoa flavanol supplementation and risk of age-related macular degeneration. An ancillary study of the COSMOS Randomized Clinical Trial. JAMA Ophthalmol. Published online March 27, 2025. doi:10.1001/jamaophthalmol.2025.0353

2. Kornzweig AL. Changes in the choriocapillaris associated with senile macular degeneration. Ann Ophthalmol. 1977;9:753-756, 759-762.

3. Friedman E, Krupsky S, Lane AM, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995;102:640-646. doi:10.1016/S0161-6420(95)30974-8

4. Grunwald JE, Metelitsina TI, Dupont C, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005;46:1033-1038. doi:10.1167/iovs.04-1050

5. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999;6:125-143. doi:10.1076/opep.6.2.125.1558

6. Wong TY. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(3):327-329. doi:10.1016/j.ajo.2009.05.012

7. Liew G, Wang JJ. Manifestaciones vasculares retinianas: ¿reflejan el estado del corazón? Rev Esp Cardiol. 2011;64:515-521. doi:10.1016/j.recesp.2011.02.014

8. Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3:34. doi:10.1186/s40662-016-0063-5

9. Hyman LG, Lilienfeld AM, Ferris FL III, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983;118:213-227. doi:10.1093/oxfordjournals.aje.a113629

10. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO. Factors associated with age-related macular degeneration. an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol. 1988;128:700-710. doi:10.1093/oxfordjournals.aje.a115023

11. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. the Rotterdam Study. Am J Epidemiol. 1995;142:404-409. doi:10.1093/oxfordjournals.aje.a117648

12. Hyman L, Schachat AP, He Q, Leske MC; Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol. 2000;118:351-358. doi:10.1001/archopht.118.3.351

13. Ferris FL II. Senile macular degeneration: review of epidemiologic features. Am J Epidemiol. 1983;118:132-151. doi:10.1093/oxfordjournals.aje.a113624

14. Katsi VK, Marketou ME, Vrachatis DA, et al. Essential hypertension in the pathogenesis of age-related macular degeneration: a review of the current evidence. J Hypertens. 2015;33:2382-2388. doi:10.1097/HJH.0000000000000766

15. The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708. doi:10.1001/archopht.1992.01080240041025

16. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110:1273-1280. doi:10.1016/S0161-6420(03)00599-2

17. van Leeuwen R, Klaver CC, Vingerling JR, et al. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol. 2004;137:750-752. doi:10.1016/j.ajo.2003.09.015

18. Colijn JM, den Hollander AI, Demirkan A, et al; European Eye Epidemiology Consortium; EYE-RISK Consortium. Increased high-density lipoprotein levels associated with age-related macular degeneration: evidence from the EYE-RISK and European Eye Epidemiology Consortia. Ophthalmology. 2019;126:393-406. doi:10.1016/j.ophtha.2018.09.045

19. Ng Yin Ling C, Lim SC, Jonas JB, Sabanayagam C. Obesity and risk of age-related eye diseases: a systematic review of prospective population-based studies. Int J Obes (Lond). 2021;45:1863-1885. doi:10.1038/s41366-021-00829-y

20. Zhang QY, Tie LJ, Wu SS, et al. Overweight, obesity, and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57:1276-1283. doi:10.1167/iovs.15-18637

21. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147-1151. doi:10.1001/jama.1996.03540140035023

22. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye (Lond). 2005;19:935-944. doi:10.1038/sj.eye.6701978

23. Walchuk C, Suh M. Nutrition and the aging retina: a comprehensive review of the relationship between nutrients and their role in age-related macular degeneration and retina disease prevention. Adv Food Nutr Res. 2020;93:293-332. doi:10.1016/bs.afnr.2020.04.003

24. Broadhead GK, Hong T, Bahrami B, Flood V, Liew G, Chang AA. Diet and risk of visual impairment: a review of dietary factors and risk of common causes of visual impairment. Nutr Rev. 2021;79:636-650. doi:10.1093/nutrit/nuaa100

25. Chareonrungrueangchai K, Wongkawinwoot K, Anothaisintawee T, Reutrakul S. Dietary factors and risks of cardiovascular diseases: an umbrella review. Nutrients. 2020;12:1088. doi:10.3390/nu12041088

26. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: a scientific statement from the American Heart Association. Circulation. 2021;144:e472-e487. doi:10.1161/CIR.0000000000001031PubMedGoogle ScholarCrossref

27. Garcia JP, Santana A, Baruqui DL, Suraci N. The cardiovascular effects of chocolate. Rev Cardiovasc Med. 2018;19:123-127. doi:10.31083/j.rcm.2018.04.3187